Published in Mediators Inflamm on June 05, 2013
The role of the blood-brain barrier in the development and treatment of migraine and other pain disorders. Front Cell Neurosci (2014) 0.81
Roads Less Traveled: Sexual Dimorphism and Mast Cell Contributions to Migraine Pathology. Front Immunol (2016) 0.79
The Neuroprotective Effect of Tetramethylpyrazine Against Contusive Spinal Cord Injury by Activating PGC-1α in Rats. Neurochem Res (2015) 0.77
Dysfunction of the neurovascular unit in ischemic stroke and neurodegenerative diseases: An aging effect. Ageing Res Rev (2016) 0.77
Salmon-derived thrombin inhibits development of chronic pain through an endothelial barrier protective mechanism dependent on APC. Biomaterials (2015) 0.76
Gene expression comparison reveals distinct basal expression of HOX members and differential TNF-induced response between brain- and spinal cord-derived microvascular endothelial cells. J Neuroinflammation (2016) 0.75
Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain (2005) 13.45
Multiple sclerosis. N Engl J Med (2000) 12.69
Inflammation and Alzheimer's disease. Neurobiol Aging (2000) 12.56
Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci (2006) 12.23
The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron (2008) 10.19
Endothelial/pericyte interactions. Circ Res (2005) 8.24
Structure and function of the blood-brain barrier. Neurobiol Dis (2009) 7.64
The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev (2005) 7.56
Pericytes regulate the blood-brain barrier. Nature (2010) 6.62
P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature (2003) 6.04
The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci (2007) 5.38
Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol (2005) 5.30
Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol (2001) 5.17
Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci (2009) 5.00
Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol (2009) 4.88
The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res (2001) 3.95
Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy. Brain (2006) 3.86
ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat Neurosci (2008) 3.78
Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J (2005) 3.60
The CNS role of Toll-like receptor 4 in innate neuroimmunity and painful neuropathy. Proc Natl Acad Sci U S A (2005) 3.59
Statins alleviate experimental nerve injury-induced neuropathic pain. Pain (2011) 3.50
Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation. Pain (2005) 3.34
Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci (2005) 3.19
Lasting blood-brain barrier disruption induces epileptic focus in the rat somatosensory cortex. J Neurosci (2004) 3.17
A role for leukocyte-endothelial adhesion mechanisms in epilepsy. Nat Med (2008) 3.16
Correlations of neuronal and microvascular densities in murine cortex revealed by direct counting and colocalization of nuclei and vessels. J Neurosci (2009) 3.10
Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul Pharmacol (2002) 2.94
Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev (2009) 2.83
TGF-beta receptor-mediated albumin uptake into astrocytes is involved in neocortical epileptogenesis. Brain (2006) 2.80
Complete Freunds adjuvant-induced peripheral inflammation evokes glial activation and proinflammatory cytokine expression in the CNS. Eur J Neurosci (2004) 2.74
Activated microglia contribute to the maintenance of chronic pain after spinal cord injury. J Neurosci (2006) 2.60
Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol (2005) 2.54
Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx (2005) 2.44
Glial-cytokine-neuronal interactions underlying the mechanisms of persistent pain. J Neurosci (2007) 2.44
Clearing amyloid through the blood-brain barrier. J Neurochem (2004) 2.40
Neuroimmune activation and neuroinflammation in chronic pain and opioid tolerance/hyperalgesia. Neuroscientist (2004) 2.40
Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution. J Neuropathol Exp Neurol (1995) 2.35
Immune and glial cell factors as pain mediators and modulators. Exp Neurol (2005) 2.30
Blood-brain barrier disruption in multiple sclerosis. Mult Scler (2003) 2.27
T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS. Proc Natl Acad Sci U S A (2008) 2.26
The effect of pain on cognitive function: a review of clinical and preclinical research. Prog Neurobiol (2011) 2.16
Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev (2011) 2.13
The blood-brain barrier and epilepsy. Epilepsia (2006) 2.05
Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling. Mol Pharmacol (2007) 1.97
Loss of the tight junction proteins occludin and zonula occludens-1 from cerebral vascular endothelium during neutrophil-induced blood-brain barrier breakdown in vivo. Neuroscience (1998) 1.94
Spinal nerve lesion alters blood-spinal cord barrier function and activates astrocytes in the rat. Pain (2006) 1.94
Multiple sclerosis. Immunol Rev (2005) 1.92
T-cell infiltration and signaling in the adult dorsal spinal cord is a major contributor to neuropathic pain-like hypersensitivity. J Neurosci (2009) 1.91
Regional neural activation defines a gateway for autoreactive T cells to cross the blood-brain barrier. Cell (2012) 1.90
The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A (2003) 1.90
Immune regulation of central nervous system functions: from sickness responses to pathological pain. J Intern Med (2005) 1.86
Epilepsy surveillance among adults--19 States, Behavioral Risk Factor Surveillance System, 2005. MMWR Surveill Summ (2008) 1.73
Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation (2003) 1.69
Staining of glial fibrillary acidic protein (GFAP) in lumbar spinal cord increases following a sciatic nerve constriction injury. Brain Res (1991) 1.67
Role of receptor internalization in opioid tolerance and dependence. Pharmacol Ther (2007) 1.66
Pain associated with multiple sclerosis: systematic review and proposed classification. Pain (2007) 1.65
Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood-brain barrier leakage and active demyelination. J Pathol (2003) 1.64
Chronic widespread pain is associated with slower cognitive processing speed in middle-aged and older European men. Pain (2010) 1.58
Targeting blood-brain barrier changes during inflammatory pain: an opportunity for optimizing CNS drug delivery. Ther Deliv (2011) 1.57
Inflammatory pain alters blood-brain barrier permeability and tight junctional protein expression. Am J Physiol Heart Circ Physiol (2001) 1.54
Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem Pharmacol (2004) 1.53
Brain endothelial cells and the glio-vascular complex. Cell Tissue Res (2008) 1.53
The possible role of glia in nociceptive processing and hyperalgesia in the spinal cord of the rat. Neuropharmacology (1994) 1.51
Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis. Arch Neurol (1993) 1.51
In vivo and in vitro effects of pilocarpine: relevance to ictogenesis. Epilepsia (2007) 1.50
Inflammation and neurovascular changes in amyotrophic lateral sclerosis. Mol Cell Neurosci (2012) 1.44
Minocycline and pentoxifylline attenuate allodynia and hyperalgesia and potentiate the effects of morphine in rat and mouse models of neuropathic pain. Eur J Pharmacol (2007) 1.44
Pericyte migration from the vascular wall in response to traumatic brain injury. Microvasc Res (2000) 1.44
Ultrastructure of blood-brain barrier and blood-spinal cord barrier in SOD1 mice modeling ALS. Brain Res (2007) 1.43
In vitro models of the blood-brain barrier. Acta Neurobiol Exp (Wars) (2011) 1.43
Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med (2012) 1.42
Nonmotor manifestations of Parkinson's disease. Ann Neurol (2008) 1.41
Temporal expression of cytokines and their receptors mRNAs in a neuropathic pain model. Neuroreport (2004) 1.40
Perfusion-weighted imaging defects during spontaneous migrainous aura. Ann Neurol (1998) 1.40
Counter-regulation of opioid analgesia by glial-derived bioactive sphingolipids. J Neurosci (2010) 1.34
Interleukin-18-mediated microglia/astrocyte interaction in the spinal cord enhances neuropathic pain processing after nerve injury. J Neurosci (2008) 1.34
Cell type-specific interleukin-1beta signaling in the CNS. J Neurosci (2004) 1.33
6-Hydroxydopamine-induced alterations in blood-brain barrier permeability. Eur J Neurosci (2005) 1.33
Peripheral nerve injury alters blood-spinal cord barrier functional and molecular integrity through a selective inflammatory pathway. J Neurosci (2011) 1.31
Wnt signaling in the vasculature. Exp Cell Res (2013) 1.29
Cyclooxygenase inhibition limits blood-brain barrier disruption following intracerebral injection of tumor necrosis factor-alpha in the rat. J Pharmacol Exp Ther (2007) 1.29
Pain in Parkinson's disease. Mov Disord (2010) 1.29
Chronic inflammatory pain leads to increased blood-brain barrier permeability and tight junction protein alterations. Am J Physiol Heart Circ Physiol (2005) 1.28
Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience (1993) 1.27
The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease. Neuroscience (2000) 1.27
Pain processing in dementia and its relation to neuropathology. Lancet Neurol (2003) 1.24
Blood-brain barrier alterations in ageing and dementia. J Neurol Sci (2009) 1.24
Spinal cord injury pain: mechanisms and management. Curr Pain Headache Rep (2012) 1.23
The distribution of Abcc6 in normal mouse tissues suggests multiple functions for this ABC transporter. J Histochem Cytochem (2003) 1.23
Abnormal endothelial tight junctions in active lesions and normal-appearing white matter in multiple sclerosis. Brain Pathol (2002) 1.23
Sodium channels contribute to microglia/macrophage activation and function in EAE and MS. Glia (2005) 1.22
Transforming growth factor-beta signaling alters substrate permeability and tight junction protein expression at the blood-brain barrier during inflammatory pain. J Cereb Blood Flow Metab (2009) 1.22
The blood-spinal cord barrier: morphology and clinical implications. Ann Neurol (2011) 1.21
Peripheral nerve injury and TRPV1-expressing primary afferent C-fibers cause opening of the blood-brain barrier. Mol Pain (2010) 1.21
Blood-brain barrier tight junctions are altered during a 72-h exposure to lambda-carrageenan-induced inflammatory pain. Am J Physiol Heart Circ Physiol (2002) 1.20
Peripheral inflammatory hyperalgesia modulates morphine delivery to the brain: a role for P-glycoprotein. J Neurochem (2007) 1.18
A role for leukocyte-endothelial adhesion mechanisms in epilepsy. Nat Med (2008) 3.16
Neurons in area V4 of the macaque translate attended visual features into behaviorally relevant categories. Neuron (2007) 1.79
Misdiagnosed chronic pelvic pain: pudendal neuralgia responding to a novel use of palmitoylethanolamide. Pain Med (2010) 1.54
p21(Waf1/Cip1/Sdi1) mediates shear stress-dependent antiapoptotic function. Cardiovasc Res (2004) 1.48
Horner syndrome following thyroidectomy. Neurol Sci (2010) 1.43
Recurrent occipital seizures misdiagnosed as status migrainosus. Epileptic Disord (2011) 1.42
Fibromuscular dysplasia as a rare cause of severe ischemic stroke in a young man. Arq Neuropsiquiatr (2011) 1.39
Single tonic-clonic seizure after energy drink abuse. Epilepsy Behav (2012) 1.39
A case of topiramate-induced epistaxis. Curr Drug Saf (2009) 1.37
CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics (2009) 1.32
Purinergic signalling in inflammation of the central nervous system. Trends Neurosci (2009) 1.32
Obesity and inflammation: evidence for an elementary lesion. Pediatrics (2006) 1.30
Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma. Clin Cancer Res (2005) 1.27
Immunomodulatory effects of etanercept in an experimental model of spinal cord injury. J Pharmacol Exp Ther (2005) 1.25
In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model. Clin Cancer Res (2004) 1.18
Sleep disorders in children with Attention-Deficit/Hyperactivity Disorder (ADHD) recorded overnight by video-polysomnography. Sleep Med (2009) 1.13
The emerging role for chemokines in epilepsy. J Neuroimmunol (2010) 1.12
African trypanosome infections of the nervous system: parasite entry and effects on sleep and synaptic functions. Prog Neurobiol (2009) 1.12
Epithelial and mesenchymal tumor compartments exhibit in vivo complementary patterns of vascular perfusion and glucose metabolism. Neoplasia (2007) 1.12
High field MRI in preclinical research. Eur J Radiol (2003) 1.12
Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury. J Pharmacol Exp Ther (2008) 1.12
alpha-Gustducin immunoreactivity in the airways. Cell Tissue Res (2004) 1.11
Impairment of ceramide synthesis causes a novel progressive myoclonus epilepsy. Ann Neurol (2014) 1.11
Attenuation in the evolution of experimental spinal cord trauma by treatment with melatonin. J Pineal Res (2005) 1.11
Acyl homoserine lactones induce early response in the airway. Anat Rec (Hoboken) (2009) 1.10
The P2Y-like receptor GPR17 as a sensor of damage and a new potential target in spinal cord injury. Brain (2009) 1.07
Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique. Pharmacogenomics (2010) 1.06
Intrathecal clonidine administration and erectile dysfunction: what is the link? Pain Physician (2013) 1.06
Evaluation of olfactory dysfunction in neurodegenerative diseases. J Neurol Sci (2012) 1.06
Phenotypic changes, signaling pathway, and functional correlates of GPR17-expressing neural precursor cells during oligodendrocyte differentiation. J Biol Chem (2011) 1.05
TNF-alpha blockage in a mouse model of SCI: evidence for improved outcome. Shock (2008) 1.05
The cellular mechanisms involved in the vasodilator effect of nebivolol on the renal artery. Eur J Pharmacol (2005) 1.04
Glycogen synthase kinase-3 beta inhibition reduces secondary damage in experimental spinal cord trauma. J Pharmacol Exp Ther (2006) 1.03
Hippocampal FGF-2 and BDNF overexpression attenuates epileptogenesis-associated neuroinflammation and reduces spontaneous recurrent seizures. J Neuroinflammation (2010) 1.02
Involvement of gD/HVEM interaction in NF-kB-dependent inhibition of apoptosis by HSV-1 gD. Biochem Pharmacol (2008) 1.02
CGS 21680, an agonist of the adenosine (A2A) receptor, decreases acute lung inflammation. Eur J Pharmacol (2011) 1.01
Effect of Apocynin, an inhibitor of NADPH oxidase, in the inflammatory process induced by an experimental model of spinal cord injury. Free Radic Res (2010) 1.01
Laryngeal chemosensory clusters. Chem Senses (2004) 1.01
Myrtucommulone from Myrtus communis exhibits potent anti-inflammatory effectiveness in vivo. J Pharmacol Exp Ther (2008) 1.01
Glycogen synthase kinase-3beta inhibition attenuates the development of ischaemia/reperfusion injury of the gut. Intensive Care Med (2007) 1.00
Identification and characterization of a specific sensory epithelium in the rat larynx. J Comp Neurol (2004) 1.00
Effect of apocynin, a NADPH oxidase inhibitor, on acute lung inflammation. Biochem Pharmacol (2010) 1.00
Evidence for the role of PI(3) -kinase-AKT-eNOS signalling pathway in secondary inflammatory process after spinal cord compression injury in mice. Eur J Neurosci (2011) 1.00
Mutation analysis of CCM1, CCM2 and CCM3 genes in a cohort of Italian patients with cerebral cavernous malformation. Brain Pathol (2010) 0.97
Evidence for the role of peroxisome proliferator-activated receptor-beta/delta in the development of spinal cord injury. J Pharmacol Exp Ther (2010) 0.97
Anti-inflammatory effect of simvastatin in an experimental model of spinal cord trauma: involvement of PPAR-α. J Neuroinflammation (2012) 0.96
MK801 attenuates secondary injury in a mouse experimental compression model of spinal cord trauma. BMC Neurosci (2011) 0.96
Effect of 17beta-estradiol on signal transduction pathways and secondary damage in experimental spinal cord trauma. Shock (2008) 0.96
Acute metabolic brain changes following traumatic brain injury and their relevance to clinical severity and outcome. J Neurol Neurosurg Psychiatry (2006) 0.95
Absence of endogenous interleukin-10 enhances secondary inflammatory process after spinal cord compression injury in mice. J Neurochem (2009) 0.95
Lennox-Gastaut syndrome with late-onset and prominent reflex seizures in trisomy 21 patients. Epilepsia (2009) 0.94
Beneficial effects of FeTSPP, a peroxynitrite decomposition catalyst, in a mouse model of spinal cord injury. Free Radic Biol Med (2007) 0.94
Prescribing pattern of anti-epileptic drugs in an Italian setting of elderly outpatients: a population-based study during 2004-07. Br J Clin Pharmacol (2010) 0.94
Glucose transporters are expressed in taste receptor cells. J Anat (2011) 0.94
NMDA receptor antagonist felbamate reduces behavioral deficits and blood-brain barrier permeability changes after experimental subarachnoid hemorrhage in the rat. J Neurotrauma (2007) 0.94
Sexual dysfunction in male patients with multiple sclerosis: a need for counseling! Int J Neurosci (2013) 0.93
Heterogeneous seizure manifestations in Hypomelanosis of Ito: report of four new cases and review of the literature. Neurol Sci (2009) 0.93
Classic hippocampal sclerosis and hippocampal-onset epilepsy produced by a single "cryptic" episode of focal hippocampal excitation in awake rats. J Comp Neurol (2010) 0.93
Effects of a metalloporphyrinic peroxynitrite decomposition catalyst, ww-85, in a mouse model of spinal cord injury. Free Radic Res (2009) 0.93
Does pilocarpine-induced epilepsy in adult rats require status epilepticus? PLoS One (2009) 0.92
Membrane cholesterol extraction decreases Na+ transport in A6 renal epithelia. Am J Physiol Cell Physiol (2005) 0.92
Modulation of nitric oxide homeostasis in a mouse model of spinal cord injury. J Neurosurg Spine (2006) 0.92
Role of natural killer cells in the pathogenesis and progression of multiple sclerosis. Pharmacol Res (2007) 0.92
Inhibitors of poly(ADP-ribose) polymerase modulate signal transduction pathways and secondary damage in experimental spinal cord trauma. J Pharmacol Exp Ther (2004) 0.91
Costameric proteins in human skeletal muscle during muscular inactivity. J Anat (2008) 0.91
Selective adenosine A2A receptor agonists and antagonists protect against spinal cord injury through peripheral and central effects. J Neuroinflammation (2011) 0.91
Increased oxidative-related mechanisms in the spinal cord injury in old rats. Neurosci Lett (2005) 0.91
Late-onset Parkinsonism in NFκB/c-Rel-deficient mice. Brain (2012) 0.91
Glucocorticoid-induced tumor necrosis factor receptor-related (GITR)-Fc fusion protein inhibits GITR triggering and protects from the inflammatory response after spinal cord injury. Mol Pharmacol (2008) 0.91
1H-MR spectroscopy in traumatic brain injury. Neurocrit Care (2011) 0.90
Liver X receptor agonist treatment regulates inflammatory response after spinal cord trauma. J Neurochem (2009) 0.90
CGS 21680, an agonist of the adenosine (A2A) receptor, reduces progression of murine type II collagen-induced arthritis. J Rheumatol (2011) 0.90
Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease. Neurobiol Dis (2005) 0.90
Modulation of NADPH oxidase activation in cerebral ischemia/reperfusion injury in rats. Brain Res (2010) 0.90
In vivo mapping of fractional plasma volume (fpv) and endothelial transfer coefficient (Kps) in solid tumors using a macromolecular contrast agent: correlation with histology and ultrastructure. Int J Cancer (2003) 0.90
Impaired filtering of distracter stimuli by TE neurons following V4 and TEO lesions in macaques. Cereb Cortex (2004) 0.89
The diffuse chemosensory system: exploring the iceberg toward the definition of functional roles. Prog Neurobiol (2010) 0.89
Secretory cells of the airway express molecules of the chemoreceptive cascade. Cell Tissue Res (2006) 0.89
The effects of oleuropein aglycone, an olive oil compound, in a mouse model of carrageenan-induced pleurisy. Clin Nutr (2011) 0.89
Effects of Liver x receptor agonist treatment on signal transduction pathways in acute lung inflammation. Respir Res (2010) 0.88
Ethyl pyruvate reduces the development of zymosan-induced generalized inflammation in mice. Crit Care Med (2009) 0.88
Effects of combination of melatonin and dexamethasone on secondary injury in an experimental mice model of spinal cord trauma. J Pineal Res (2007) 0.88
Melatonin reduces stress-activated/mitogen-activated protein kinases in spinal cord injury. J Pineal Res (2009) 0.87
Evidence for the role of mitogen-activated protein kinase signaling pathways in the development of spinal cord injury. J Pharmacol Exp Ther (2008) 0.87
Magnetic resonance imaging of the rat Harderian gland. J Anat (2002) 0.87
Four-week trunk-specific rehabilitation treatment improves lateral trunk flexion in Parkinson's disease. Mov Disord (2010) 0.87
Clinical differentiation and outcome evaluation in vegetative and minimally conscious state patients:the neurophysiological approach. Funct Neurol (2013) 0.87
Melatonin reduces hyperalgesia associated with inflammation. J Pineal Res (2010) 0.87
Involvement of 5-lipoxygenase in spinal cord injury. J Neuroimmunol (2005) 0.87
Role of endogenous ligands for the peroxisome proliferators activated receptors alpha in the secondary damage in experimental spinal cord trauma. Exp Neurol (2005) 0.87
Brain-derived neurotrophic factor and TrkB receptor in experimental autoimmune encephalomyelitis and multiple sclerosis. J Neurol Sci (2009) 0.86
GW0742, a high-affinity PPAR-δ agonist, mediates protection in an organotypic model of spinal cord damage. Spine (Phila Pa 1976) (2012) 0.86
Three-dimensional volume rendering of the ankle based on magnetic resonance images enables the generation of images comparable to real anatomy. J Anat (2009) 0.86
Role of mitochondrial Na+ concentration, measured by CoroNa red, in the protection of metabolically inhibited MDCK cells. J Am Soc Nephrol (2005) 0.86
Cerebral perfusion alterations in epileptic patients during peri-ictal and post-ictal phase: PASL vs DSC-MRI. Magn Reson Imaging (2013) 0.86
Predictive biomarkers of recovery in traumatic brain injury. Neurocrit Care (2012) 0.86
Neuroinflammation and brain infections: historical context and current perspectives. Brain Res Rev (2010) 0.86